Hinge Health, Inc. SEC Filings

Hinge Health, Inc., a digital MSK and migraine care company, reported strong results for the three and six months ended June 30, 2026. Revenue was 212,817 and 395,124 (in thousands), with gross profit of 183,949 and 338,182 (in thousands). Income from operations reached 40,440 and 72,509 (in thousands), and net income was 43,690 and 78,818 (in thousands), compared with net losses of 575,651 and 558,512 (in thousands) in 2025.

Net cash provided by operating activities rose to 144,496 (in thousands) for the first half of 2026. As of June 30, 2026, cash and cash equivalents were 286,224 (in thousands) and marketable securities totaled 187,909 (in thousands). Deferred revenue increased to 416,466 (in thousands), and stockholders’ equity improved to 344,328 (in thousands) as redeemable convertible preferred stock was fully converted. The company repurchased and retired 2,934,671 Class A shares for 131,491 (in thousands) and expanded its share repurchase authorization to an aggregate 496.5 million of Class A common stock.

Management highlights risks including a history of accumulated deficits, heavy reliance on AI-driven care, evolving healthcare and telehealth regulation, supplier concentration for its Enso device, and dependence on health-plan partners. A dual class structure concentrates voting control with the founders, and the company expects to become a large accelerated filer and cease emerging growth company status as of December 31, 2026.

Hinge Health, Inc. reported that President James Pursley had 831 shares of Class A common stock withheld and cancelled on August 1, 2026 at $74.71 per share to satisfy federal and state tax withholding from vested restricted stock units, in an exempt Section 16b-3(e) transaction. Following this disposition, he directly holds 739,235 shares of Class A common stock.

Hinge Health, Inc. Chief Financial Officer James Budge reported a single exempt transaction involving Class A Common Stock. On 2026-08-01, 4,614 shares were relinquished and cancelled at $74.71 per share to satisfy federal and state tax withholding obligations arising from the vesting of restricted stock units. Following this tax-withholding disposition, he holds 426,172 shares of Class A Common Stock directly. The transaction is exempt under Section 16b-3(e) and reflects payment of tax liabilities rather than an open-market sale.

Hinge Health, Inc. reported a strong second quarter for 2026, with revenue of $212.8 million, an increase of 53% year-over-year. GAAP income from operations was $40.4 million, compared with a GAAP operating loss of $580.7 million a year earlier, and non-GAAP income from operations rose to $61.5 million with a 29% non-GAAP operating margin. GAAP diluted net income per share was $0.52, while non-GAAP diluted net income per share was $0.59. Free cash flow reached $99.6 million, and cash, cash equivalents, marketable securities and restricted cash totaled $475.6 million as of June 30, 2026.

Management raised full-year 2026 guidance to $856–$860 million in revenue and $236–$244 million in non-GAAP income from operations, implying 46% and 101% year-over-year growth at the midpoints. The board expanded the share repurchase program to a total authorization of $496.5 million, leaving $300.0 million available for future repurchases. Hinge Health also signed a definitive agreement to acquire Cylinder Health, Inc. for $105 million in cash, aiming to enter gastrointestinal care with an integrated GI program expected to launch in 2027.

Mecklenburg Gabriel M.I. reported acquisition or exercise transactions in this Form 4 filing.

Hinge Health, Inc. reported that executive chairman and co‑founder Gabriel M.I. Mecklenburg received a grant of 944,250 performance‑based restricted stock units. Each unit represents a contingent right to one share of Class B Common Stock, earned and vested on July 27, 2026 after certified performance criteria, with settlement deferred. The PSUs do not expire; they either vest or are cancelled prior to the vesting date.

Hinge Health, Inc. CEO and Co‑Founder Daniel Antonio Perez reported the vesting of 944,250 performance‑based restricted stock units on July 27, 2026, settling into Class B Common Stock. He relinquished 509,423 Class B shares at $74.3100 per share to cover tax withholding, and holds awards including 3,777,002 PSUs and 358,445 Class B shares held indirectly through his spouse.

BlackRock, Inc. has reported a significant ownership position in Hinge Health Inc. Class A stock on a Schedule 13G. BlackRock beneficially owns 2,992,772 shares of Class A stock, representing 5.5% of the class as of June 30, 2026.

BlackRock has sole voting power over 2,928,636 shares and sole dispositive power over all 2,992,772 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends and sale proceeds, but no single client holds more than five percent of Hinge Health’s outstanding common shares.

Insight Holdings Group, LLC and affiliated Insight Venture funds, as ten percent owners of Hinge Health, Inc., reported a coordinated sequence of derivative conversions and open-market sales of Class A Common Stock on July 7 and July 9, 2026. The group converted derivative positions into an aggregate 426,171 Class A shares and sold the same number of shares in open-market transactions at prices around $90–$91 per share, according to the transaction data. The transactions are reported as indirect holdings, with further ownership details referenced in Exhibit 99.1.

Hinge Health, Inc. director Tyler Sloat acquired 246 shares of Class A Common Stock through the settlement of fully vested restricted stock units on July 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program.

Following this equity grant, Sloat directly holds 10,210 shares of Class A Common Stock. This is a routine, compensation-related award rather than an open-market stock purchase or sale.